Molecular Biology Reports, Journal Year: 2025, Volume and Issue: 52(1)
Published: April 25, 2025
Language: Английский
Cancers, Journal Year: 2024, Volume and Issue: 16(13), P. 2478 - 2478
Published: July 7, 2024
The rise of drug resistance in cancer cells presents a formidable challenge modern oncology, necessitating the exploration innovative therapeutic strategies. This review investigates latest advancements overcoming mechanisms employed by cells, focusing on emerging modalities. intricate molecular insights into resistance, including genetic mutations, efflux pumps, altered signaling pathways, and microenvironmental influences, are discussed. Furthermore, promising avenues offered targeted therapies, combination treatments, immunotherapies, precision medicine approaches highlighted. Specifically, synergistic effects combining traditional cytotoxic agents with molecularly inhibitors to circumvent pathways examined. Additionally, evolving landscape immunotherapeutic interventions, immune checkpoint adoptive cell is explored terms bolstering anti-tumor responses evasion mechanisms. Moreover, significance biomarker-driven strategies for predicting monitoring treatment underscored, thereby optimizing outcomes. For future direction paradigms, current focused prevailing challenges improving patient outcomes, through an integrative analysis these
Language: Английский
Citations
33
Medical Oncology, Journal Year: 2024, Volume and Issue: 41(2)
Published: Jan. 9, 2024
Language: Английский
Citations
19
Pathology - Research and Practice, Journal Year: 2024, Volume and Issue: 254, P. 155174 - 155174
Published: Jan. 26, 2024
Breast cancer remains a major global health challenge. Its rising incidence is attributed to factors such as delayed diagnosis, the complexity of its subtypes, and increasing drug resistance, all contributing less-than-ideal patient outcomes. Central progression breast are epigenetic aberrations, which significantly contribute resistance emergence stem cell traits. These include alterations in DNA methylation, histone modifications, expression non-coding RNAs. Understanding these changes crucial for developing advanced management strategies despite their complexity. Investigating modifications offers potential novel diagnostic markers, more accurate prognostic indicators, identification reliable predictors treatment response. This could lead development new targeted therapies. However, this requires sustained, focused research efforts navigate challenges understanding carcinogenesis underpinnings. A deeper mechanisms can revolutionize personalized medicine. significant improvements care, including early detection, precise disease stratification, effective options.
Language: Английский
Citations
16
Phytomedicine Plus, Journal Year: 2025, Volume and Issue: unknown, P. 100754 - 100754
Published: Jan. 1, 2025
Language: Английский
Citations
2
ACS Pharmacology & Translational Science, Journal Year: 2024, Volume and Issue: 7(4), P. 967 - 990
Published: March 19, 2024
Precision medicine is transforming colorectal cancer treatment through the integration of advanced technologies and biomarkers, enhancing personalized effective disease management. Identification key driver mutations molecular profiling have deepened our comprehension genetic alterations in cancer, facilitating targeted therapy immunotherapy selection. Biomarkers such as microsatellite instability (MSI) DNA mismatch repair deficiency (dMMR) guide decisions, opening avenues for immunotherapy. Emerging liquid biopsies, artificial intelligence, machine learning promise to revolutionize early detection, monitoring, selection precision medicine. Despite these advancements, ethical regulatory challenges, including equitable access data privacy, emphasize importance responsible implementation. The dynamic nature with its tumor heterogeneity clonal evolution, underscores necessity adaptive strategies. future lies potential enhance patient care, clinical outcomes, understanding this intricate disease, marked by ongoing evolution field. current reviews focus on providing in-depth knowledge various diverse approaches utilized against at both biochemical levels.
Language: Английский
Citations
15
Advances in medical diagnosis, treatment, and care (AMDTC) book series, Journal Year: 2024, Volume and Issue: unknown, P. 122 - 164
Published: March 11, 2024
Cancer, a critical health concern, necessitates safer, more effective treatments. This chapter explores the anticancer potential of traditional Thai plants, which, despite being underresearched, show significant promise. It focuses on bioactive compounds and their efficacy against various cancer types. The categorizes these plants based active components reviews both laboratory animal studies to understand underlying mechanisms involved in inhibiting cell growth, inducing death, preventing tumor blood vessel formation. Clinical trials supporting findings are also highlighted. Given improve or innovate treatments, present encouraging prospects. However, further research is essential confirm safety approaches. These suggest that could lead development innovative drugs, signaling advancements therapy.
Language: Английский
Citations
13
Biomedicines, Journal Year: 2025, Volume and Issue: 13(1), P. 86 - 86
Published: Jan. 1, 2025
Urothelial carcinoma (UC) is the most common histological subtype of bladder tumors; however, cancer represents a heterogeneous group diseases with at least 40 distinct subtypes. Among these, 2022 World Health Organization classification urinary tract tumors identifies range less subtypes invasive UC, formerly known as variants, which are considered high-grade tumors, including squamous cell, small-cell, sarcomatoid urothelial, micropapillary, plasmacytoid, and urachal carcinomas, adenocarcinoma. Their accurate diagnosis critical for risk stratification therapeutic decision-making, histologies associated poorer outcomes than conventional UC. Despite importance precise diagnosis, high-quality evidence on optimal treatments remains limited owing to their rarity. In particular, neoadjuvant adjuvant chemotherapy have not been well characterized, prospective data scarce. For advanced-stage diseases, clinical trial participation strongly recommended address lack robust evidence. Advances in molecular pathology development targeted therapies immunotherapies reshaped our understanding subtypes, spurring efforts identify predictive biomarkers guide personalized treatment strategies. Nevertheless, management rare subgroups challenging because they frequently excluded from trials. localized disease, curative options such surgical resection or radiotherapy available; become more recurrence metastasis, where systemic therapy primarily used control disease progression palliate symptoms. Herein, we present recent advances urothelial non-urothelial also explore current guiding emphasize challenges perspectives future
Language: Английский
Citations
1
Biomedical Reports, Journal Year: 2025, Volume and Issue: 22(3)
Published: Jan. 8, 2025
The advent of personalized and precision medicine has revolutionized oncology treatment gynecological cancer. These innovative approaches tailor treatments to individual patient profiles beyond genetic markers considering environmental lifestyle factors, thereby optimizing therapeutic efficacy minimizing adverse effects. Precision uses advanced genomic technologies such as next‑generation sequencing perform comprehensive tumor profiling. This allows identification distinct mutations, expression patterns signaling pathway alterations, revealing the complex molecular landscape cancer ovarian, cervical uterine A major challenge in treating these cancers is their inherent heterogeneity, which can influence behavior, therapy response prognosis. aims overcome this by identifying biomarkers drivers for targeted selection. For example, breast (BRCA) gene mutations ovarian guided use poly (ADP‑ribose) polymerase inhibitors, leading more effective with fewer side Similar therapies immunotherapies have also been developed cancer, marking progress toward care. Future directions emphasize importance profiling development therapies. By understanding unique features each patient, clinicians select most strategies improve outcomes quality life.
Language: Английский
Citations
1
Advances in Cancer Biology - Metastasis, Journal Year: 2025, Volume and Issue: unknown, P. 100136 - 100136
Published: Feb. 1, 2025
Language: Английский
Citations
1
Functional & Integrative Genomics, Journal Year: 2025, Volume and Issue: 25(1)
Published: March 1, 2025
Language: Английский
Citations
1